The Protocol
Weekly · Free
A weekly read on peptide science

Know what your peptide is actually doing.

You've heard ten things about the same compound. Half from people selling it. We give you the truth. Backed by science and studies. Not trying to sell you a product. Read in five minutes.

5 min read Tue 6 AM ET Sources cited Free forever
✓

You're in.

Check your inbox for the welcome email. First issue lands next Tuesday at 6 AM ET.

Built for you

If any of this sounds like you, you're in the right place.

The peptide world has more noise than signal right now. Forums contradict each other. Vendors hype everything. Your doctor probably doesn't know what BPC-157 is. We built The Protocol for the person who wants the truth, not the pitch.

❖
You've watched 100 videos of creators saying different things about the same compound and walked away more confused than when you started.
❖
You want to know exactly what's happening in your body when you inject. Not just what the box says.
❖
Your doctor either doesn't know what peptides are and can't answer, or doesn't know what they are and says they're evil.
❖
You've spent money on peptides without knowing if they were even real. You're done with that.
❖
You'd rather read one good study than a hundred forum opinions from anonymous accounts.
❖
You want to be the person other people text when they have a peptide question.
What you get

Ten sections. Same rhythm. Every week.

Different compound, different stack, different deep cut. Same predictable format so you always know where to find what matters. Read in five minutes. Save it forever.

01  ·  This Week in Peptides

The big story, decoded.

FDA pathway updates, Phase 3 readouts, policy moves. Neutral reporter tone, primary sources cited.

02  ·  Peptide of the Week

One compound, picked by you.

Mechanism, half-life, who it's for, what people actually report. The most-requested compound wins the slot every week.

03  ·  In the Lab

Three new studies, three sentences each.

Fresh peer-reviewed research. Tight summaries. Direct links to PubMed and primary sources.

04  ·  Stack Spotlight

A working protocol and why it works.

Real community stacks: goal, compounds, sequencing logic, what people report by week 12.

05  ·  Vendor Watch

The trust layer.

Industry purity alerts, failed third-party tests, COA red flags. The section that gets forwarded.

06  ·  Deep Cut + Reader Q + The Long Game

The stuff nobody else bothers with.

Obscure peptide history. One reader question answered with first-name credit. One non-peptide longevity concept that compounds.

A taste of Issue 001

The strongest GLP-1 ever tested just hit 28.7%.

Issue 001 leads with Retatrutide's TRIUMPH-4 Phase 3 readout. Plus three studies you missed, the "lose fat, keep muscle" stack the community is running, a Vendor Watch on the Reta purity scandal, and a Deep Cut on how a 1992 paper about Gila monster venom built the $50B GLP-1 industry.

Issue 001  ·  May 26, 2026  ·  5 min read

A peptide just hit 28.7% weight loss.
That's the highest number ever published.

It's also not FDA approved, the supply is full of fakes, and the people running it are doing one specific thing right.

In this issue
01
Trial · Retatrutide hits 28.7% body weight loss in TRIUMPH-4 Phase 3
02
Research · BPC‑157 decoded, plus 3 new studies linked
03
Stack · The "lose fat, keep muscle" protocol the community is running
04
Alert · Sub-90% Retatrutide is in the supply chain right now
05
Deep cut · How lizard venom built the $50B GLP-1 industry
Full issue lands in your inbox after signup
Why this exists

The peptide newsletter most labs won't write.

Watch 100 videos. 100 creators saying 100 different things about the same compound. Open a vendor site. Every compound promises the world. Open a study. Buried in jargon you can't translate without three other tabs open.

The Protocol closes that loop. Real studies, plain English, cited at every claim. So you stop guessing and start knowing what's actually in the syringe, what it's actually doing, and whether it's worth your money.

The newsletter is free, independent of any vendor's catalog, and built reader-first. Subscribers vote with replies. The most-requested compound becomes next week's deep dive.

Independent
No sponsored sections. No paid placements. Compounds covered whether anyone sells them or not.
Sourced
Every claim links to NEJM, PubMed, ClinicalTrials.gov, or primary research. Click through, read it yourself.
Reader-Built
Every issue ends with a vote. Reply with a peptide. Your pick can become next week's deep dive.
No Vendor Pitches
Zero "buy now" CTAs in the issue. The newsletter is the product. Nothing to upsell, nothing to push.
Real questions

Things people ask before they sign up.

Short answers. No fluff.

Will you spam me?
No. One email per week, Tuesday at 6 AM ET. One-click unsubscribe in every issue.
Who publishes this?
The Protocol is published by NLL Labs, a small research peptide lab with public third-party testing. The newsletter is editorial, independent of the shop. Compounds get covered whether NLL carries them or not.
Will you give me dosing advice?
No. We're not licensed practitioners. The Protocol covers science and frameworks. Specific dosing, cycle design, and individual response require knowing your body, not a newsletter conversation.
Can I request a peptide?
Yes. Every issue ends with a vote. Reply with any peptide you're curious about, including ones nobody sells. Most-requested compounds get featured first.
Where do past issues live?
Right here, on this site, with permanent links for sharing. Every issue archived.
I'm new to peptides. Is this for me?
Yes. Plain English first, technical depth where it matters. Built for the curious, not just the experienced.

Be the most educated person in the room about peptides.

Five minutes a week. Sources cited. Reader-built. Free forever.

✓

You're in.

First issue lands next Tuesday at 6 AM ET.